The Drug-Induced Respiratory Disease Website and App

Frequency - Incidence

Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases

Evidence level/grade

Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic

XLV.a

Pleural effusion (uni- or bilateral) (can accompany DI-LDs)

Publications

Merchant MS, Wright M, Baird K, Wexler LH, Rodriguez-Galindo C, Bernstein D, Delbrook C, Lodish M, Bishop R, Wolchok JD, Streicher H, Mackall CL

Phase I Clinical Trial of Ipilimumab in Pediatric Patients with Advanced Solid Tumors.

Clinical cancer research : an official journal of the American Association for Cancer Research 2016 Mar 15;22;1364-70 — 2016 Mar 15 — 1364-70

Yun S, Vincelette ND, Mansour I, Hariri D, Motamed S

Late onset ipilimumab-induced pericarditis and pericardial effusion: a rare but life threatening complication.

Case reports in oncological medicine 2015;2015;794842 — 2015 — 794842